Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06662396 · ClinicalTrials.gov registry record · Phase 1
A Study of Diltiazem With a Single Dose of MK-6552 in Healthy Adult Participants (MK-6552-007)
A Phase 1 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT06662396 is a Phase 1 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 14 participants.
The verdict
NCT06662396, a Phase 1 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
The main goal of this study is to learn what happens to MK-6552 in a person's body over time (a pharmacokinetic or PK study). Researchers want to know what happens to MK-6552 in healthy adults when a single dose of MK-6552 is given with multiple doses of diltiazem. The researchers believe that multiple doses of diltiazem will not affect the highest amount of MK-6552 in the blood.
Interventions
- DRUG Diltiazem
- DRUG MK-6552
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2024-06-13 |
| Est. Completion | 2024-09-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06662396
The ClinicalTrials.gov registry entry for NCT06662396 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Diltiazem is the first listed.
NCT06662396 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06662396 about?
NCT06662396 is a clinical study titled "A Study of Diltiazem With a Single Dose of MK-6552 in Healthy Adult Participants (MK-6552-007)". The main goal of this study is to learn what happens to MK-6552 in a person's body over time (a pharmacokinetic or PK study). Researchers want to know what happens to MK-6552 in healthy adults when a single dose of MK-6552 is given with multiple doses of diltiazem. The researchers believe that multi...
What is the current status of trial NCT06662396?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2024-06-13. Estimated completion is 2024-09-27.
What interventions are being tested in trial NCT06662396?
The interventions under investigation include: Diltiazem (DRUG), MK-6552 (DRUG).
Who is sponsoring clinical trial NCT06662396?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.